NCT04668508 is a Phase 2 clinical trial of Anlotinib in Malignant Brain Stem Tumor, sponsored by Zhejiang Cancer Hospital.

Who is sponsoring NCT04668508?

NCT04668508 is sponsored by Zhejiang Cancer Hospital.

What drugs are being tested in NCT04668508?

Interventions in NCT04668508: Anlotinib.

What condition does NCT04668508 study?

NCT04668508 studies Malignant Brain Stem Tumor, Glioma.

Is NCT04668508 still recruiting?

NCT04668508 is currently status unknown. Last updated 16 December 2020.

Last reviewed 2020-12-16 · How we verify

NCT04668508

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anlotinib to Malignant Brainstem Glioma

Status unknown Phase 2 Last updated 16 December 2020

What this trial tests

Phase 2 trial testing Anlotinib in Malignant Brain Stem Tumor in 25 participants. Status unknown.

Timeline

24 November 2020

Primary endpoint
30 June 2022

1 January 2023

Quick facts

Lead sponsor	Zhejiang Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	24 November 2020
Primary completion	30 June 2022
Estimated completion	1 January 2023
Sites	1 location across China

Drugs / interventions tested

Anlotinib — full drug profile →

Conditions studied

Malignant Brain Stem Tumor — all drugs for Malignant Brain Stem Tumor →
Glioma — all drugs for Glioma →

Sponsor

Zhejiang Cancer Hospital

Who can join

Adults 18 to 70, any sex, with Malignant Brain Stem Tumor or Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-arm, open-label, phase II study of anlotinib combined with radiation in the treatment of patients with malignant brainstem glioma. Twenty five patients will be enrolled in the study who is diagonsis with malignant brainstem glioma. The primary objective includes disease control rate (DCR), the role of antinib combined with radiotherapy in improving quality of life and 6-month progression-free survival rate. The secondary objective include overall survival (OS), toxicity profile. Exploratory objectives include the use of plasma specimens and cerebrospinal fluid (if possible) to detect biomarkers predicting the efficacy of anlotinib.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Verify or expand the search:

Other trials of Anlotinib

Trials testing the same drug.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting

Other Zhejiang Cancer Hospital trials

Trials by the same sponsor.

NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04668508 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
Last refreshed: 16 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04668508.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing